Open randomized study of pyrimethamine–sulphadoxine vs. pyrimethamine–sulphadoxine plus probenecid for the treatment of uncomplicated Plasmodium falciparum malaria in children
- 29 April 2004
- journal article
- clinical trial
- Published by Wiley in Tropical Medicine & International Health
- Vol. 9 (5) , 606-614
Abstract
Summary: Background Increasing drug resistance in Plasmodium falciparum has necessitated renewed search for cheap, effective alternatives to commonly available antimalarials, chloroquine and pyrimethamine–sulphadoxine, for the treatment of malaria in Africa. Probenecid, an inhibitor of organic anion transporters and multiresistance‐associated proteins, can chemosensitize P. falciparum to pyrimethamine and sulphadoxine in vitro, but the clinical significance is unclear. We assessed the safety, treatment efficacy, and effects on gametocyte carriage of adding probenecid to pyrimethamine–sulphadoxine.Methods We evaluated 151 children aged 12 years or younger who had uncomplicated P. falciparum malaria. Patients were randomly assigned pyrimethamine–sulphadoxine (25 mg/kg of the sulphadoxine component) or pyrimethamine–sulphadoxine as above plus probenecid 20–25 mg/kg of bodyweight in two divided doses daily for 3 days. The primary endpoints were parasitological cure rates on days 14 and 28.Results Both regimens were well tolerated; no child was withdrawn because of drug intolerance. Fever (1.9 ± 1.1 vs. 2.4 ± 1.2 days, P = 0.02) and parasite clearance (2.3 ± 0.9 vs. 2.7 ± 1.1 days, P = 0.04) were significantly shorter, and the parasitological cure rate on day 14 (96.2%vs. 83.5%, P = 0.02) but not day 28 (79.4%vs. 72.6%, P = 0.4), was significantly higher in children treated with pyrimethamine–sulphadoxine–probenecid than in those treated with pyrimethamine–sulphadoxine. Gametocyte carriage was similar with both treatment regimens.Conclusions The combination of pyrimethamine–sulphadoxine, and probenecid, at a relatively moderate dose, improved treatment efficacy but had no effect on gametocyte carriage. The pyrimethamine–sulphadoxine–probenecid combination merits further evaluation as a potential treatment for use in Nigeria.Keywords
This publication has 34 references indexed in Scilit:
- Point mutations in the pfcrt and pfmdr-1 genes of Plasmodium falciparum and clinical response to chloroquine, among malaria patients from NigeriaPathogens and Global Health, 2003
- Asymptomatic, recrudescent, chloroquine-resistantPlasmodium falciparuminfections in Nigerian children: clinical and parasitological characteristics and implications for the transmission of drug-resistant parasitesPathogens and Global Health, 2003
- Chemosensitization of Plasmodium falciparum by Probenecid In VitroAntimicrobial Agents and Chemotherapy, 2003
- Pyrimethamine–sulfadoxine resistance in Plasmodium falciparum: what next?Trends in Parasitology, 2001
- Plasmodium falciparum in Kenya: high prevalence of drug-resistance-associated polymorphisms in hospital admissions with severe malaria in an epidemic areaPathogens and Global Health, 2001
- Enhanced efficacy of chloroquine-chlorpheniramine combination in acute uncomplicated falciparum malaria in childrenTransactions of the Royal Society of Tropical Medicine and Hygiene, 1997
- Evidence for selection for the tyrosine-86 allele of the pfmdr 1 gene of Plasmodium falciparum by chloroquine and amodiaquineParasitology, 1997
- Intramuscular sulfadoxine-pyrimethamine in uncomplicated chloroquine-resistant falciparum malaria during pregnancyTransactions of the Royal Society of Tropical Medicine and Hygiene, 1993
- IN-VITRO CHLOROQUINE AND MEFLOQUINE-RESISTANT PLASMODIUM FALCIPARUM IN NIGERIAThe Lancet, 1987
- Plasmodium falciparum infection not responding to chloroquine in NigeriaTransactions of the Royal Society of Tropical Medicine and Hygiene, 1985